M&T Bank Corp decreased its stake in Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) by 3.7% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 27,907 shares of the biopharmaceutical company’s stock after selling 1,084 shares during the period. M&T Bank Corp’s holdings in Alexion Pharmaceuticals were worth $3,419,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of ALXN. Cornerstone Advisors Inc. boosted its stake in Alexion Pharmaceuticals by 47.4% in the third quarter. Cornerstone Advisors Inc. now owns 964 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 310 shares during the last quarter. NEXT Financial Group Inc boosted its stake in Alexion Pharmaceuticals by 66.1% in the second quarter. NEXT Financial Group Inc now owns 1,106 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 440 shares during the last quarter. Bellwether Investment Group LLC bought a new stake in Alexion Pharmaceuticals during the second quarter worth approximately $172,000. Charlemagne Capital Ltd. bought a new stake in Alexion Pharmaceuticals during the second quarter worth approximately $191,000. Finally, Evercore Wealth Management LLC boosted its stake in Alexion Pharmaceuticals by 5.0% in the second quarter. Evercore Wealth Management LLC now owns 1,735 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 83 shares during the last quarter. Institutional investors own 94.85% of the company’s stock.

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) traded down 2.39% during midday trading on Wednesday, reaching $122.59. 1,636,720 shares of the company’s stock traded hands. The firm has a market capitalization of $27.48 billion, a PE ratio of 74.75 and a beta of 1.45. The stock’s 50-day moving average price is $122.56 and its 200 day moving average price is $128.72. Alexion Pharmaceuticals Inc. has a one year low of $110.56 and a one year high of $193.45.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.04 by $0.19. The business had revenue of $799 million for the quarter, compared to analysts’ expectations of $787.07 million. Alexion Pharmaceuticals had a net margin of 12.46% and a return on equity of 10.58%. The business’s revenue for the quarter was up 19.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.16 EPS. On average, equities research analysts expect that Alexion Pharmaceuticals Inc. will post $4.64 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “M&T Bank Corp Sells 1,084 Shares of Alexion Pharmaceuticals Inc. (ALXN)” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this story can be read at https://www.thecerbatgem.com/2016/11/30/mt-bank-corp-sells-1084-shares-of-alexion-pharmaceuticals-inc-alxn.html.

A number of equities research analysts have commented on the stock. Piper Jaffray Cos. set a $176.00 price target on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Sunday, November 6th. Vetr lowered shares of Alexion Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $150.62 price objective on the stock. in a research note on Wednesday, August 3rd. Zacks Investment Research lowered shares of Alexion Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Wednesday, November 2nd. Deutsche Bank AG initiated coverage on shares of Alexion Pharmaceuticals in a research note on Thursday, November 3rd. They issued a “buy” rating and a $164.00 price objective on the stock. Finally, FBR & Co reaffirmed a “market perform” rating and issued a $130.00 price objective on shares of Alexion Pharmaceuticals in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $173.59.

In other news, EVP Julie O’neill sold 650 shares of the stock in a transaction that occurred on Friday, September 2nd. The shares were sold at an average price of $126.29, for a total value of $82,088.50. Following the transaction, the executive vice president now owns 35,384 shares in the company, valued at approximately $4,468,645.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Leonard Bell sold 37,317 shares of the stock in a transaction that occurred on Friday, November 4th. The stock was sold at an average price of $140.38, for a total transaction of $5,238,560.46. Following the completion of the transaction, the director now owns 440,936 shares in the company, valued at approximately $61,898,595.68. The disclosure for this sale can be found here. Company insiders own 4.41% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.